Poly(a-L-glutamic acid) (PGA) was grafted with amino acid and ofigopeptide spacers up to 5 amino acids with the use of ~,~I-~arbony~diimidazo~e and 2~3-dihydro-1,2-bentisoth~azole-3~n-l~l-dioxide (saecharin~ as an additive, and these polypeptides were characterized. The antitumor antibiotic adriamycin was covalently coupled via an amide bond onto PGA and onto the grafted polymers with the use of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ); these conjugates were characterized. The conjugates containing Gly-Gly--L-Leu spacer arms did yield free adriamycin upon digestion with papain. Adriamy~in gave fairly stable complexes with PGA-~driamy~in and branched po~ypeptide-adriamycin conjugates; these complexes were characterized.
INTRODUCTION

Major problems
in the administration of cytostatic agents are the lack of specificity of the drug for the tumor cell, the toxic side effects and the development of resistence of tumors for a particular drug. Extracellular polymeric release systems can be applied to maintain constant levels of the drug in a particular body compartment for extended periods of time. Examples of these systems are the well known DNA. anthracycline complexes developed by Trouet et al. [ 11. The release of the drug from these systems is at least partially governed by the clearance of plasma from the free drug, which in turn leads to further dissociation of the DNA complexes. In principle, constant levels of the drug can also be obtained by bioerosion of degradable polymer matrices or by extracellular cleavage of covalently bound polymer-drug conjugates.
Although peak concentrations of the drug can be avoided using these systems and a decrease in systemic toxicity can be expected, a more selective administration of the drug would be advantageous.
This could be achieved with the use of endocellular release systems, which release the drug after being incorporated by tumor cells. Only after uptake by tumor cells should the conjugates degrade and release the parent drug.
Tumor cells show a higher degree of uptake of macromolecules by endocytosis than their normal counterp~ts do. After internalization of the polymer-drug conjugate, a phagosome is formed which fuses with a lysosome, and subsequently the polymer-drug conjugate is exposed to a mixture of at least 40 digestive enzymes at an acidic pH (4) (5) .
Information on the presence and activity of specific enzymes in the lysosomal compartments can be used to design polymer- drug conjugates in which the drug is coupled to the macromolecular carrier through spacers which can be easily cleaved by the enzymes involved [ 21. Macromolecular prodrugs can be designed which, by virtue of the presence of high levels of specific enzymes at the tumor cell membrane (y-glutamyl transferase) [3] or near the tumor (plasmin), rapidly release the drug at the membrane or in the immediate surroundings of the tumor [4] . Problems which still exist are the competitive uptake of macromolecular prodrugs by endocytosing cells, e.g. RES, which in principle can be avoided by the coupling of appropriate antibodies against the tumor cells onto the polymer-drug conjugate.
In this paper we have concentrated on the development of high molecular weight prodrugs of adriamyc~ using polyps-L-glutami~ acid) as a biodegradable carrier and different peptides as spacers. These systems were characterized with respect to composition and load of adriamycin by spectroscopic and chemical methods. The interpolation of appropriate spacers between carrier and the bioactive compound to meet optimal requirements for lysosomal attack and release of the drug has been applied by several investigators [2, 10, 311. Thus, Trouet et al. [lo] have shown that optimal spacers consisted of tri-and tetra-LLeu-terminal peptides attached to succinylated e-lysine groups of albumin. Kopecek [2] described the peptide-spacer dependent release of p-nitroaniline from N-( 2-hydroxypropyl)methacrylamide using thiolproteinases (Cathepsin B, L and H) as important representatives of the lysosomal enzyme population Because both the length and the composition of the spacer are of great importance we have synthesized and characterized a number of conjugates with various spacer arms (l-5 amino acid residues). Tyrosine was incorporated in two of the systems to enable labeling with radioactive tracers which should aid in the study of biodegradation of the conjugate (Table 2) and the amides anticipated. A slight excess of EEDQ in the reaction mixture also gave rise to the formation of transparent gels after 24 h at which time virtually all of the drug has been incorporated into the polymer.
RESULTS AND DISCUSSION a. Prodrug design
However, the crosslinks present in these gels are much more resistant towards hydrolysis than those of the acid anhydride type. It was concluded, that these crosslinks were, at least partly, of an estertype nature. It was found that these ester bonds are selectively hydrolysed in the course of 2-3 days in the presence of imidazole.
The hydrolysed material readily passed a 0.45 pm Millipore filter and the conjugate was purified and isolated by dialysis, ultrafiltration, chromatography and lyophylization.
The UV spectrum and the molar extinction were essentially the same as those of the free drug. Both the pure conjugates and mixtures with the free drug did follow Lambert Beer's law. These findings enabled accurate measurements of the bound drug in the conjugate. In a high frequency NMR spectrum (500 MHz) both the C' B-methyl doublet of the daunosamine moiety and the Me0 singlet (aglyconic portion) were discernible. Results are given in Table 2 . In early preparations we were faced with difficulties in removing small amounts of free (extractable) drug from the conjugates. These mounts seemed to be bound to the conjugate by relatively stable charge transfer complexes (adriamycin itself exists as dimers in solution 132, 331). By analogy with relatively stable anthracycline-DNA complexes [ 1, 53, the surprising stability of the present conjugate-free drug complexes can be explained by the additional formation of ion pairs (COO-, NH:). Both the presence of covalently bound drug and free carboxylic acid groups are required for the formation of these complexes. Addition of the free drug to PGA led to the formation of a voluminous precipitate. Thus, apart from being a prodrug, the conjugate itself may also serve as a carrier for the free drug. These conjugate complexes are readily prepared either by (a) the mere addition of Firstly, in view of the expense of the drug, a route which allows coupling of adriamycin in the very last step of the synthesis is more attractive than being engaged in a tedious multistep synthesis in which considerable amounts of the anthracycline are lost. Secondly, the preparation of carriers, which already contain the spacer arms desired will, eventually, be attractive for use in applications with other drugs, In the present approach, we preferred the use of commercially available C-unprotected ofigopeptides.
To discriminate between the carboxylic groups of PGA and those of the oligopeptides introduced, preactivation of PGA prior to addition of the oligopeptide is essential.
As mentioned above, the preactivation of lateral carboxylic acid groups in PGA by CD1 proved to be successful, but gave rise to extensive fragmentation of the peptide chain. By analogy with other methods of pr~a~tivat~on~ a number of additives were tried. Saccharin (2,3-dihydro-1,2-b~n~isoth~a-zole-3-on-l,l-dioxide) proved to be very successful. diimidazolides, which in turn reactivate the C-terminal of the spacer arms giving the saccharin imides anticipated.
The chemistry of the cascade coupling method is depicted in Schemes 3 and 4. Oligopeptide spacer arms containing up to 5 amino acid residues (Gly-Tyr--Gly--GlyLeu) were readily prepared by this method (Table  2) using Gly-Tyr and Gly-GlyLeu in the CDI-saccharin and PDCP cascade methods, respectively. Degrees of incorporation of both oligopeptide fragments were obtained from the proton integrals attributable to appropriate isolated signals in the 'H-NMR spectra (e.g. Tyr-Ar-H and Leu-CH, vs. Gly-fl-CH2 and total of all integrals, Fig.  1 ). However, in one experiment (Table 2 ) in which the first spacer fragment (GlyTyr) was coupled in 77 mole percent, a part of the second spacer fragment (GlyLeu) may be coupled directly to the carboxylic groups which are left unreacted in the first coupling step. A slight modification of the method was necessary using glycine. The latter amino acid was applied using the corresponding t-butyl ester, rather than its TMG salt. The protecting group was removed quantitatively with the use of trifluoroacetic acid.
The grafted polymers were isolated either as the sodium or as the pyridinium salts. In contrast to PGA, the free acids of these polymers were sticky gums which were difficult to handle.
Finally, adriamycin was coupled to the grafted polymers (pyridinium salts) with the use of EEDQ, and isolated, purified and analysed for the drug as described for PGA with slight modifications. Results are given in Table 2 .
In contrast to the conjugates in which the drug was attached directly onto the carrier, the prodrugs in which peptide spacers were interpolated between the PGA backbone and the drug (Fig. 2) readily yielded free adriamycin upon digestion with a relatively aspecific protease like papain.
The voluminous coloured conjugates were stable at -20°C over prolonged periods of time. However, the batches derived from --_ high molecular weight PGA (1M, 200,000) had a tendency to age, resulting in slow or even poor solubility in water and the reformation of microgel particles. The branched conjugates also had a tendency to give charge transfer complexes with free adriamycin (Table 3) , albeit not with the extreme stability as was found for the conjugates not containing the spacer arms. Surprisingly, these complexes were more stable upon storage and did redissolve more readily than the conjugates from which they were prepared. Thus, apart from being interesting devices both in terms of controlled extracellular release of the (complexed) drug and endocellular release of the (covalently bound) drug, the present complexes are stable formulations at physiological pH for both the prodrug and free adriamycin. 
MATERIALS AND METHODS
Tetrahydrofuran
Copolymer of L-glutamic acid and 3'-N-(5-L-glutaminyl) adriamycin
Polyglutamic acid (200 mg, 1.55 meq) was dissolved in dimethylformamide (2-5 ml, depending on the molecular weight of the polymer).
The viscosity must be such that mechanical manipulation and stirring in a small reaction vial is possible. Free adriamycin was generated in a separate reaction vial from its hydrochloric acid salt (54 mg, 0.093 mmol) in dimethylformamide (2 ml) containing N-ethyl morpholine (20 ~1, 0.16 mmol), and subsequently transferred to the polymer solution. Additional dimethylformamide (200 ~1) may be necessary to transfer virtually all of the adriamycin. The resultant solution was stirred for 3 h, EEDQ (26 mg, 0.11 mmol) was added, and the solution was stirred overnight. In preparations when using high molecular weight polyacid or larger excesses of EEDQ a translucent solid red gel containing cross-links of both the acid anhydride and 14-ester types may result. The solution or the gel, which was fragmentated mechanically, was stirred into a phosphate buffer (80 ml, 100 mM, pH 7) solution containing imidazole (1 g) and the mixture was kept in the dark at 6°C for 3-5 days with occasional shaking. A diluted sample from the bulk gave the same UV spectrum and molar extinction coefficient for bound adriamycin (E490 = 84900 1 mol-' cm-') as found for the free drug. The clear red solution was dialyzed against deionized water, freed from minute amounts of microgel particles (Millipore HA filter 0.45 pm), concentrated and washed by molecular filtration (Millipore immersible filters CX-10). TLC analysis may reveal small amounts of free adriamycin bound to the polymer by R-complexes.
The conjugate can be purified by passing slowly the solution through an ion exchange column (100 X 4 cm, Dowex HCRW-2, sodium form). Finally, the pure conjugate is isolated by concentration (molecular filtration) to a small volume and lyophilization giving a brickred voluminous mass; yield: 80-90% (recovery, by weight), 90-100% (conversion to bound adriamycin; UV). Attempt to digest the copolymer (5 mg) with papain (5 mg) in phosphate buffer (pH 5.4) did not yield free adriamycin (TLC).
In a 500 MHz (DzO) 'H-NMR spectrum a small sharp singlet on the positive slope of the HOD resonance attributable to MeO-CH3 (aglycone; 6 3.99 ppm) and a doublet (daunosamine; C'G-CH3, 6 1.164, Jf5,16, 6.35 Hz) were discernable).
Other resonances were obscured by the resonances of polyglutamic acid, Table 2 . The copolymer above (210 mg) was dissolved in water (10 ml) and the solution was transferred to a small flask fitted with a screw cap holding a molecular filter (Millipore immersible filter CX-10) attached to a vacuum line, a magnetic stirring bar and a septum outlet. Solutions were then introduced into the stirred cell with the aid of a syringe at a very slow rate which was controlled by the efflux from the stirred cell. In this manner a solution of adriamycin hydrochloride (40 mg, 0.069 mmol), water (5 ml), phosphate buffer (2 ml, 100 mM, pH 7) and water (250 ml), respectively, were introduced.
No adriamycin was. present in the filtrate of the cell, indicating that all of the drug added is accomodated by the polymer in the form of ll-complexes. The solution of the macromolecular complex was filtered (Millipore HA 0.45 pm) with the aid of a stirred pressure cell to remove any microgel particles, and the filtrate and washings were again concentrated to a small volume with the aid of an immersible molecular filter as described above. The polymeric drug was finally isolated by lyophylization (240 mg,, 95%). The material behaved as one entity in dialysis, molecular filtration and gel chromatography (Sephadex GlO), but was readily decomposed into the conjugate and free adriamycin by ionexchange chromatography (polystyrene, sulphonate type, sodium form) and TLC. The UV spectrum of the polymeric complex was virtually the same as that of adriamycin or its conjugate, Table 3 .
Method b (incomplete covalent linkage of the drug onto ~lyglutamic acid)
Polyglutamic acid (ZOO mg, 1.55 mmol) was dissolved in dimethylformamide (1 ml) and a suspension of adriamycin, generated from its hydrochloric acid salt (108 mg, 0.186 mmol), N-ethyl morpholine (25 ~1) in dimethylformamide (4 ml) was added. The solution was stirred for an hour, EEDQ (25 mg, 0.093 mmol) was added, and stirring was continued overnight. The contents of the vial were dissolved in phosphate buffer (100 ml, 100 ti, pH 7.0) and the solution was dialysed exhaustively with internal stirring by a slow stream of nitrogen. The solution was passed through a ~~lipore filter (HA 0.45 pm) and prior to lyophylization the filtrate was concentrated by molecular filtration as described in Method a. The material prepared was indistinguishable from that prepared according to Method a. The reaction between the two components was accompanied with the evolution of carbon dioxide and with a dramatic decrease in the viscosity of the solution.
Then, a solution of Gly-Gly-LLeu N,N,N',N'-tetramethyl guanidinium salt (TMG', prepared by the slow addition of ~,~,~',~'-te~~ethyl guanidine (TMG; 30 ~1, 0.25 mmol) to a stirred suspension of finely powdered Gly-Gly-It-Leu in dimethylformamide (4 ml)) was added. Stirring was continued for three days. mg sample of the product was dissolved in a small volume of deuterium oxide and freeze dried prior to 'H-NMR analysis. The 'H-NMR spectra of the products were in accordance with the structures assigned. Degrees of substitution were calculated from proton integrals attributable to structure elements in spacer (e.g. leucine-CH3) and backbone.
See Table  2 and Fig. 1 .
Polyglutamic acid glycine graft
Polymeric saccharin imides were generated from polyglutamic acid (129 mg, 1 mmol eq) as described above. A solution of glycine t-butyl ester hydrochloride (170 mg, 1.05 mmol) and TMG (131 ~1, 1.05 mmol) in dimethylformamide (2 ml) was added, and the reaction mixture was stirred for 3 days. The clear solution was diluted with dimethylformamide (10 ml) and then added dropwise to a vigorously stirred aqueous phosphate buffer (600 ml, 100 miV, pH 7.0). stirring of the viscous solution should be possible). Then, N-ethylmorpholine (0.1 mmol eq) and adriamycin hydrochloric acid salt (0.1 mmol eq) are added. After dissolution of all solids, EEDQ (0.11 mmol eq) was added. The extent of incorporation of the drug can be monitored by TLC analysis (a minute sample is taken in phosphate buffer (50 ~1) and subjected to two-dimensional TLC analysis (same solvent), to account for artefacts caused by the presence of dimethylformamide and salts present). In some experiments the addition of more N-ethylmorpholine and EEDQ may improve the coupling yield of adriamycin.
The reaction mixture was stirred for an additional 24 h, then added to phosphate buffer, and further processed, isolated and analyzed for covalently bound adriamycin (UV) as described for the copolymer of L-glutamic acid and 3'-N-(5-L-glutaminyl) adriamycin. All compounds are believed to be microheterogeneous with respect to molecular weight, degree of substitution of both spacer and drug, but all behave as one entity in dialysis, chromatography and ultrafiltration. All compounds were sterilized by filtration (Millipore HA 0.45 pm), and should be stored in the dark in a freezing chest. Frozen solutions are more resistant to ageing than the solid compounds. Results are given in Table 2 .
Incubation of the PGA-Gly-Gly-Leu (5 mg) with papain (5 mg) in phosphate buffer (pH 5.4) gave rise to the formation of adriamycin (TLC) within 5 min. 
